A global biopharmaceutical company, Cortendo AB, is happy to announce a scientific paper reporting on pre-clinical study that the details the glucose-lowering effect of BP-2001, an orally administered genetically modified probiotic being studied for the treatment of type 1 and type 2 diabetes is being published by the Journal Diabetes.
“The pre-clinical data show that BP-2001 demonstrated the ability to reprogram intestinal endocrine cells into glucose-responsive insulin-secreting cells without affecting the normal function of nearby cells.” Said Matthew Pauls, President and CEO of Cortendo. “These results provide evidence that BP-2001 has the potential to be a safe and effective oral treatment for diabetes, and we plan to submit an investigational new drug (IND) application with the FDA later this year.”
Cortendo is focused on commercializing and developing innovative produces for orphan endocrine diseases, led by COR-003 (levoketoconazole), which is in Phase 3 development for endogenous Cushing’s syndrome. The company is potentially exploring opportunities to work with partners to expand its orphan disease portfolio. The company is also exploring opportunities to out-license BP-2001.
BioPancreate Inc. is a wholly-owned US subsidiary of Cortendo AB. It is developing novel, orally administered biological therapeutics to treat endocrine disorders utilizing modified probiotic human bacteria. BioPancreate’s main product for diabetes is modifications of naturally occurring bacteria that exist in the human gastrointestinal tract. Natural probiotics are safe for humans when taken orally. BioPancrete gives a human biological peptide directly into the gastrointestinal tract, which transforms the intestinal enter endocrine cells into glucose-responsive insulin-secreting cells, i.e. pancreas-like beta cells.
The development of pharmaceuticals brings significant risk. Failure at any stage during development and commercialization due to safety or clinical efficacy issues. Delays from requirements from regulatory authorities, difficulties in recruiting patients into clinical trials due to physician or patient preferences or competing products, not anticipated by the company. It isn’t for sure that Corendo will receive marketing and regulatory approvals necessary to commercialize of produce these products and regulatory approvals may be denied, delayed, limited or revoked completely.